Volume shifting up in CHM , much more cashed up play than NYR . Has more shares on issue but not overly excessive.
Nice suite of potential cancer assets/drugs in the pipeline.
When Biotechs turn this should do very handsomely
was trading at 35 cents before biotechs got slaughtered in 2023.
10cents+ conservative expectation before yrs end, dyor
